|
gptkbp:instanceOf
|
gptkb:vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:alsoKnownAs
|
gptkb:Sputnik_V
|
|
gptkbp:approvedBy
|
gptkb:Algeria
gptkb:Argentina
gptkb:Bahrain
gptkb:Belarus
gptkb:Bolivia
gptkb:Egypt
gptkb:Gabon
gptkb:Guatemala
gptkb:Hungary
gptkb:India
gptkb:Iran
gptkb:Jordan
gptkb:Kazakhstan
gptkb:Kyrgyzstan
gptkb:Laos
gptkb:Lebanon
gptkb:Mexico
gptkb:Moldova
gptkb:Mongolia
gptkb:Montenegro
gptkb:Morocco
gptkb:Nepal
gptkb:Nicaragua
gptkb:Pakistan
gptkb:Palestine
gptkb:Paraguay
gptkb:Philippines
gptkb:Russia
gptkb:San_Marino
gptkb:Serbia
gptkb:Sri_Lanka
gptkb:Syria
gptkb:Tunisia
gptkb:Turkey
gptkb:United_Arab_Emirates
gptkb:Uzbekistan
gptkb:Vanuatu
gptkb:Venezuela
gptkb:Vietnam
gptkb:Zimbabwe
|
|
gptkbp:category
|
gptkb:COVID-19_vaccines
gptkb:COVID-19_pandemic_in_Russia
2020 introductions
Russian inventions
|
|
gptkbp:composition
|
recombinant adenovirus vectors encoding SARS-CoV-2 spike protein
|
|
gptkbp:countryOfOrigin
|
gptkb:Russia
|
|
gptkbp:developedBy
|
gptkb:Gamaleya_Research_Institute
|
|
gptkbp:dosesRequired
|
2
|
|
gptkbp:effect
|
91.6% (published interim analysis)
|
|
gptkbp:firstRegistered
|
2020-08-11
|
|
gptkbp:intervalBetweenDoses
|
21 days
|
|
gptkbp:regimen
|
heterologous prime-boost
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
mild flu-like symptoms
pain at injection site
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
gptkb:viral_vector_vaccine
|
|
gptkbp:vectorUsed
|
gptkb:adenovirus_serotype_26
adenovirus serotype 5
|
|
gptkbp:WHOStatus
|
not approved by WHO as of 2024
|
|
gptkbp:bfsParent
|
gptkb:Sputnik_V
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gam-COVID-Vac
|